Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553304 | 0.89 | PPARG (0.44) | ACHEPPARGPPARDPPARAALDH1A1 | |
| SCHEMBL12736108 | 0.85 | DRD2 (0.58) | DRD2DRD4ACHEPARP11ALDH1A1 | |
| SCHEMBL13369061 | 0.81 | SMN1; SMN2 (0.43) | DRD2DRD4SMN1; SMN2GFERACHE | |
| SCHEMBL8892613 | 0.81 | SMN1; SMN2 (0.43) | DRD2DRD4SMN1; SMN2GFERACHE | |
| SCHEMBL5540616 | 0.81 | SMN1; SMN2 (0.43) | DRD2DRD4SMN1; SMN2GFERACHE | |
| SCHEMBL91440 | 0.81 | SMN1; SMN2 (0.50) | DRD2DRD4SMN1; SMN2GFER | |
| SCHEMBL6616742 | 0.80 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL1426114 | 0.79 | SMN1; SMN2 (0.49) | DRD2DRD4SMN1; SMN2GFERALDH1A1 | |
| SCHEMBL9328756 | 0.79 | KDM4E (0.45) | DRD2DRD4SMN1; SMN2GFERACHE | |
| SCHEMBL4190017 | 0.78 | SMN1; SMN2 (0.51) | DRD2DRD4SMN1; SMN2GFERHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262053-B1 | IMIDAZOTHIADIAZOLE COMPOUNDS AS PAR4-INHIBITORS | UNIV MONTREAL (CA) | 2022-10-05 | — | — | EP | disclosed |
| US-11059977-B2 | Near-infrared-absorbing dye, optical filter, and imaging device | AGC Inc. (JP) | 2021-07-13 | — | — | US | disclosed |
| US-20180237457-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS | UNIVERSITE DE MONTREAL (CA) | 2018-08-23 | — | — | US | disclosed |
| EP-3262053-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS | Université de Montréal (CA) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016134450-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS | Université de Montréal (CA) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016134450-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS | Université de Montréal (CA) | 2016-09-01 | — | — | WO | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7572806-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080096913-A1 | PPAR active compounds | PLEXXIKON, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| CN-1204121-C | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1253547-A | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096913-A1 | PPAR active compounds | PPARG, PPARD, PPARA | DRD2 1428/4885DRD4 1486/4885SMN1; SMN2 4719/4885 |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | DRD2 440/4885DRD4 1124/4885SMN1; SMN2 1261/4885 |
| US-11059977-B2 | Near-infrared-absorbing dye, optical filter, and imaging device | CRY2, CRY1, LBR | DRD2 7/4885DRD4 5/4885SMN1; SMN2 3755/4885 |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | DRD2 777/4885DRD4 351/4885SMN1; SMN2 3642/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | DRD2 1428/4885DRD4 1486/4885SMN1; SMN2 4719/4885 |
| US-20180237457-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS | F12, F2, F3 | DRD2 2293/4885DRD4 1330/4885SMN1; SMN2 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.